Understanding merger control remedies in China.
other
Where this comes from
- Record sourced from PubMed, PMID 41270040.
- Also identified by DOI 10.1371/journal.pone.0336795 and PMC identifier 12637943.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We identified 8 merger cases with remedies in China for a period from the time when the Anti-monopoly Law was enacted in 2008-2018, and about 150 other merger cases corresponding to these 8 cases in their respective industries but approved without remedies. We then use the latter data to construct a counterfactual for the former to compare the factually observed level of competition after the merger decision with that derived from the counterfactual, based on a method called the synthetic control method (SCM). The exercise allows us to assess the remedies' effectiveness. We find that overall the remedies are effective, but the structural remedies' effect tends to be more abrupt and pronounced than behavioral remedies.
Medical subject headings
- Economic Competition
- Industry